TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) Director Joseph Capper bought 25,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $30,500.00. Following the purchase, the director owned 179,827 shares of the company’s stock, valued at approximately $219,388.94. The trade was a 16.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
TELA Bio Trading Down 3.1%
Shares of NASDAQ TELA opened at $1.25 on Friday. TELA Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.69. The company has a debt-to-equity ratio of 8.82, a quick ratio of 2.38 and a current ratio of 2.99. The company has a market cap of $56.42 million, a price-to-earnings ratio of -1.62 and a beta of 1.36. The business’s 50 day moving average price is $0.79 and its 200-day moving average price is $0.80.
TELA Bio (NASDAQ:TELA – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The business had revenue of $19.29 million for the quarter, compared to analysts’ expectations of $20.01 million. On average, sell-side analysts expect that TELA Bio, Inc. will post -0.76 earnings per share for the current year.
Analyst Ratings Changes
View Our Latest Report on TELA Bio
Institutional Investors Weigh In On TELA Bio
Several hedge funds have recently made changes to their positions in TELA. Perkins Capital Management Inc. increased its stake in shares of TELA Bio by 1.5% during the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock valued at $879,000 after buying an additional 20,910 shares during the period. WealthTrust Axiom LLC lifted its stake in TELA Bio by 39.1% in the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after acquiring an additional 90,650 shares during the period. UP Strategic Wealth Investment Advisors LLC bought a new position in TELA Bio during the 2nd quarter worth about $91,000. BlackRock Inc. bought a new position in TELA Bio during the 2nd quarter worth about $281,000. Finally, Stonepine Capital Management LLC purchased a new position in TELA Bio during the 2nd quarter valued at about $1,996,820. 94.35% of the stock is currently owned by hedge funds and other institutional investors.
About TELA Bio
TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.
The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.
Read More
- Five stocks we like better than TELA Bio
- MarketBeat Week in Review – 09/14 – 09/18
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
